Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study (PHOMIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04067843|
Recruitment Status : Recruiting
First Posted : August 28, 2019
Last Update Posted : August 28, 2019
|Condition or disease||Intervention/treatment||Phase|
|Postoperative Wound Infection Deep Incisional Surgical Site Prosthesis and Implants Surgical Site Infection Prosthetic Joint Infection||Procedure: Photodynamic treatment||Not Applicable|
Background. Periprosthetic joint infections are increasing due to our elderly population with the need of a joint prosthesis. These infections are difficult to treat, because bacteria are able to be sessile (biologically inactive) in the biofilms formed within one day on the orthopedic implant surface. Notably, the current available antibiotics do not penetrate the biofilm or are not active against the sessile form of bacteria - rifampicin being the only antibiotic being active. Therefore, prevention is key. In the current paradigm, bacteria from the skin surface or dermis - such as Staphylococcus aureus, coagulase-negative staphylococci, or Cutibacterium sp. - contaminate the peri-implant tissue during surgery. In an ongoing study with the Orthopedic University Hospital Balgrist (manuscript in preparation), the investigators found that the common practice of skin antisepsis is ineffective to eliminate skin bacteria before surgery. Strikingly, the skin bacteria hide in sebaceous or sweat glands. Photodynamic treatment has recently gained attention in the treatment of acne patients, a disease of the pilosebaceous unit, in which also Cutibacterium acnes is implicated. The photodynamic treatment works here on the one hand through a long-lasting destruction of the sebaceous glands, and on the other hand due to anti-inflammatory and antimicrobial effects.
Hypothesis. The investigators hypothesize that photodynamic treatment improves skin antisepsis before surgical implantation of foreign material by reduction of persistent skin colonizing bacteria through the destruction of the sebaceous and sweat glands and by its bactericidal effects Overall and specific objectives. The overarching aim of this research project is to prevent orthopedic implant-associated infections. The specific aim is to evaluate the effect of photodynamic treatment on colonizing bacteria immediately after surgical skin antisepsis (aim 1) and 3 weeks later (aim 2). In aim 3, the investigators will evaluate phylogenetic similarity of same bacterial species before and after photodynamic treatment if they persist.
Methods. The investigators will collect scrapings from the skin surface and quantitatively evaluate bacterial species and density before and after photodynamic treatment in combination with skin antisepsis of povidone-iodine/alcohol, in aim 1 immediately after skin antisepsis, and in aim 2, 21 days after photodynamic treatment. For aim 2, the investigators will additionally evaluate changes of sebaceous and sweat glands after photodynamic treatment using histopathology. To evaluate phylogenetic similarity of same bacterial species before and after photodynamic treatment, the investigators will investigate the core genome using whole genome sequencing.
Relevance and outlook. The current study will investigate if photodynamic treatment is able to improve preoperative skin preparation to decrease surgical site infections in hip arthroplasty surgery. A decrease of implant-associated infections has multiple benefits, among others reduced morbidity, mortality and lower health costs. This study shall provide the fundament for a prospective cohort study of patients with planned hip arthroplasty for investigating the effect of photodynamic treatment before skin antisepsis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||The investigator will collect scrapings from the skin surface and quantitatively evaluate bacterial species and density before and after photodynamic treatment in combination with skin antisepsis of povidone-iodine/alcohol, in aim 1 immediately after skin antisepsis, and in aim 2, 21 days after photodynamic treatment. For aim 2, the investigators will additionally evaluate changes of sebaceous and sweat glands after photodynamic treatment using histopathology.|
|Masking:||None (Open Label)|
|Official Title:||Effects of Photodynamic Therapy on the Human Inguinal Skin Microbiome to Improve Antiseptic Effect - a Pilot Study|
|Actual Study Start Date :||August 8, 2019|
|Estimated Primary Completion Date :||June 30, 2020|
|Estimated Study Completion Date :||July 31, 2021|
Experimental: Photodynamic treatment
Skin microbiome after photodynamic treatment before and after skin antisepsis
Procedure: Photodynamic treatment
Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
Other Name: PDT
- 1. Microbiome analysis immediately after photodynamic treatment [ Time Frame: Day 1 ]1.1. bacterial density and species before and after photodynamic treatment and antisepsis skin preparation on the same day
- 2. Microbiome analysis 3 weeks after photodynamic treatment [ Time Frame: Day 21±3 after PDT treatment ]2.1. bacterial density and species after 21 days after photodynamic treatment before and after skin antisepsis
- Phylogenetic comparisons of isolated bacteria [ Time Frame: Day 1 and Day 21 ]whole genome sequencing and phylogenetic comparisons of isolated bacteria in different swabs
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04067843
|Contact: Yvonne Achermann, MD||0041 44 255 34 email@example.com|
|Contact: Laurence Imhof||0041 44 255 31 firstname.lastname@example.org|
|Principal Investigator:||Yvonne Achermann, MD||University Hospital Zurich, Department of Infectious Diseases and Hospital Epidemiology|